CA
NZ
UK
AU
IND
US
C4 Therapeutics (NASDAQ:CCCC) Penny Stock, a clinical-stage biotech developing protein-degrading drugs, presented new biomarker data for its lead drug, cemsidomide, at the 23rd International Myeloma Society Annual Meeting, with shares dipping amid broader small-cap biotech weakness. Biomarkers are measurable biological signals showing whether a …
CDT Equity Inc. Penny Stock (NASDAQ:CDT), a small biopharmaceutical development company, sold off heavily after the board approved a 1-for-25Reverse Stock Splitto ensure continued compliance with Nasdaq's bid-price rule, which requires aListed Stockto trade at or above $1.00. The stock never recovered during the …
Aquestive Therapeutics (NASDAQ:AQST) Penny Stock, a member of the Russell 2000 small-cap index, slipped after filing an 8-K attaching its latest corporate presentation, which walks investors through the status of Anaphylm, the company's experimental epinephrine film for severe allergic reactions. The headline point is …
Acadia Pharmaceuticals Inc. (NASDAQ:ACAD), a member of the S&P SmallCap 600 index, fell for a second consecutive day after reporting that its drug remlifanserin missed the main goal of a Phase 2 trial in Alzheimer's disease psychosis. The company called the data "Phase 3 …
● Dr. Edward M. Kaye notified Stoke Therapeutics' board on September 22, 2026 of his intent to resign as a Class III director, effective September 23, 2026, with the filing stating the resignation was not the result of any disagreement with the company.
● Teladoc Health disclosed that Chief Legal Officer Adam Vandervoort will resign effective November 1, 2026, with the filing stating the departure is made with good reason under his executive severance agreement.
● NervGen's audit committee determined on September 25, 2026 that financial statements for fiscal years 2025 and 2024, plus unaudited interim results for Q2 2026, should no longer be relied upon.
● NeuroSense's PARADIGM Phase 2b trial showed a statistically significant 65% reduction in mortality risk for ALS patients continuously treated with PrimeC, with median survival of 36.3 months versus 21.4 months for the placebo-then-crossover arm.
● Moleculin Biotech disclosed on September 25, 2026 that its lead candidate Annamycin's antitumor activity against pancreatic cancer is partially driven by CD8+ T cell cytotoxicity, an immune-system mechanism.
● IHL-42X received FDAFast Track Designationin December 2025 for obstructive sleep apnea, following completion of the Phase 2 portion of the RePOSA trial in July 2025, which enrolled 121 subjects across 16 U.S. sites.
Please wait processing your request...